The Result of the Surgical Treatment for Non-small Cell Lung Cancer.
- Author:
Jin Kyue PARK
1
;
Jung Ku JO
;
Kong Soo KIM
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Medical College of Chonbuk National University, Korea.
- Publication Type:Original Article
- Keywords:
Carcinoma, non-small cell, lung;
Survival rate
- MeSH:
Adenocarcinoma;
Carcinoma, Large Cell;
Carcinoma, Non-Small-Cell Lung*;
Carcinoma, Squamous Cell;
Hemoptysis;
Humans;
Incidence;
Korea;
Lung Neoplasms;
Male;
Mastectomy, Segmental;
Mortality;
Pneumonectomy;
Postoperative Complications;
Prevalence;
Survival Rate;
Thorax;
Tolnaftate
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
1997;30(9):899-907
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently, primary lung cancer has increased markedly in incidence and prevalence in korea. From July 1979 to June 1996, 183 patients were diagnosed and operated for primary non-small cell lung cancer, and evaluated clinically. 1. There were 164 males and 19 females(M:F=8.6:1), and the peak incidence of age was 50th and 60th decade of life(73.7%). 2. Most of symptoms were respiratory, whitch were cough(44.8%), chest pain(30.1%), dyspnea(20.8%), hemoptysis or blood tinged sputum(19.7%), sputum(15.3%), and asympto- matic cases were 12.0%. 3. Histopathologically, sguamous cell carcinoma was 68.9%, adenocarcinoma 19.7%, bronchioloalveolar cell carcinoma 2.2%, adenosguamous cell carcinoma 1.6%, and large cell carcinoma 7.7%. 4. In the operation, pneumonectomy was 41.0%, lobectomy 42.1%, bilobectomy 13.1%, segmentectomy or wedge resection 1.6%, and explore tharacotomy 2.2%, and the overall resectability was 97.8%. 5. Postoperative complications were developed in 31.9%, and operative mortality was 1.6%. 6. In postoperative stagings, stage I was 38.3%, stage II 14.8%, stage III a 31.1%, and stage III b 15.8%. 7. The overall cumulative survival rates were 1 year 77.8%, 3 year 42.7%, and 5 year 39.5%. The 5 year survival rate according to stage were stage I 53.0%, stage II 46.5%, stage III a 28.2%, and stage III b 13.8%(p<0.05), according to operation method were lobectomy 45.0%, and pneumonectomy 30.3%(p<0.05), and according to mediastinal involvement were N1 32.0%, and N2 11.1%(p<0.05). The 5 year survival rate according to histologic type were squamous cell carcinoma 43.1%, adenocarcinoma 23.3%, and large cell carcinoma 30.3%(p>0.05).
